Escalon Medical Corp. Reports 5.7% Revenue Growth to $12.74 Million for Fiscal Year Ending June 30, 2026

Escalon Medical Corp. reported a consolidated net revenue of approximately $12.74 million for the fiscal year ending June 30, 2026, marking a 5.7% increase from the previous year’s revenue of $12.05 million. This growth was primarily driven by a $1.26 million increase in sales of Sonomed products and services, although it was partially offset by declines in Trek product sales and AXIS revenue, which decreased by $518,000 and $51,000, respectively. The cost of revenue also rose, totaling $7.17 million, or 56.3% of total revenue, compared to $6.54 million, or 54.3% of total revenue in the prior year, attributed to a change in product mix.

The company’s operating expenses saw an increase as well, with marketing, general, and administrative expenses rising by 8.6% to $5.02 million, largely due to higher compensation, legal, and advertising costs. Conversely, research and development expenses decreased significantly by 33.5% to $501,000, reflecting a reduction in consulting expenses related to the AXIS platform, despite increased investment in ultrasound development. A notable operational highlight was the sale of the AXIS software business for $3 million, resulting in a net gain of approximately $2.81 million before taxes, which contributed positively to the company’s liquidity.

Escalon Medical's workforce remained stable, employing 40 individuals as of June 30, 2026, with 19 in manufacturing, 15 in general and administrative roles, and 6 in sales and marketing. The company’s liquidity improved significantly, with cash on hand increasing to approximately $3.07 million from $546,000 in the previous year. The current ratio also improved to 2.94:1, up from 1.72:1, indicating a stronger short-term financial position. The company’s total equity rose to $5.93 million, compared to $1.92 million in the prior year, reflecting a positive shift in financial health.

Looking ahead, Escalon Medical Corp. anticipates continued growth driven by its strategic focus on product innovation and market expansion. However, the company has acknowledged risks related to regulatory compliance, competition, and potential supply chain disruptions due to recent tariffs and trade measures. Management is actively monitoring these factors and is prepared to implement strategies to mitigate their impact. The company’s outlook remains cautiously optimistic, with plans to leverage its improved liquidity and operational efficiencies to support future growth initiatives.